Effect of Implementing an Aerobic Training Program and Administering Ginkgo Biloba Extract on Plasma Concentrations of LDL and HDL in HIV Positive Patients Undergoing Antiretroviral Treatment at the HIV Unit of Hospital Civil Fray Antonio Alcalde

The administration of antiretroviral drugs (ART) has significantly prolonged the life expectancy of people living with human immunodeficiency virus (HIV) and delayed the progression towards Acquired Immune Deficiency Syndrome (AIDS). However, this has led to the emergence of other conditions, such as dyslipidemia, among individuals undergoing ART. Dyslipidemia is commonly managed with statin therapy, which has not been reported to have pharmacological interactions with ART. Additionally, ginkgo biloba extract (GBS) has been observed to improve blood lipid concentrations, and aerobic exercise training (EXA) interventions have shown positive modifications in these values.
Given this context, the present study aims to investigate the potential positive effects of an aerobic training program and the consumption of ginkgo biloba extract on plasma lipid concentrations in HIV-positive individuals. The study seeks to provide insights into novel strategies for managing dyslipidemia in this population.

开始日期2022-05-01

申办/合作机构

University of Guadalajara

NCT05398874

/ CompletedN/AIIT

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis

To assess the efficacy and safety of the Ginkgo biloba extract in patients with Knee OA.

开始日期2021-11-01

申办/合作机构

University of Kufa

NCT04192656

/ Recruiting临床4期IIT

The Effect of Positive Airway Pressure on Idiopathic Sudden Sensorineural Hearing Loss Comorbided With Obstructive Sleep Apnea: A Clinical Randomized Controlled Study

This clinical randomized controlled study is to explore the effect of positive airway pressure(PAP) on patients in Beijing Tsinghua Changgung Hospital diagnosed with both idiopathic sudden sensorineural hearing loss comorbided(ISSHL) and obstructive sleep apnea(OSA) between Dec. 2019 to Dec. 2029.

开始日期2019-11-01

申办/合作机构-

100 项与银杏叶提取物相关的临床结果

登录后查看更多信息

100 项与银杏叶提取物相关的转化医学

登录后查看更多信息

100 项与银杏叶提取物相关的专利（医药）

登录后查看更多信息

项与银杏叶提取物相关的文献（医药）

2020-01-01·Evidence-based complementary and alternative medicine : eCAM4区 · 医学

Chinese Herbal Injections for Primary Nephrotic Syndrome in Adults: A Systematic Review and Network Meta‐Analysis

4区 · 医学

ArticleOA

作者: Han, Shisheng ; Lu, Yanhua ; Xu, Yanqiu ; Yao, Tianwen ; Wang, Yi ; Lu, Yan

Primary nephrotic syndrome (PNS) is a common renal disease that presents with heavy proteinuria and hypoalbuminemia. Despite notable advances in its treatment, some patients show poor responses and clinical outcomes when treated with conventional Western medicine (WM). Chinese herbal injections (CHIs) have been reported to have beneficial effects for PNS. The aim of the present study was to comprehensively determine the efficacy and safety of CHIs for PNS in adults using a network meta‐analysis approach. PubMed, Embase, the Cochrane library, and four Chinese databases were systematically searched to identify randomized controlled trials (RCTs) using CHIs for treatment of PNS published before June 1, 2019. Quality assessment of the identified RCTs was performed according to the Cochrane Handbook. Pooled odds ratios (OR) or mean differences (MD) with corresponding 95% confidence intervals (CI) were calculated for discrete or continuous variables, respectively. The primary outcome was complete/total remission and secondary outcomes were serum albumin and urinary protein excretion. The surface under the cumulative ranking curve (SUCRA) value and cluster analyses were used to rank treatment by probability. Eighty‐five studies involving 11 CHIs and 5801 subjects were included. Compared with WM alone, CHI plus WM showed an improved complete/total remission rate as well as higher serum albumin and lower 24‐hour urinary protein excretion, except in the following: Yinxingye injection plus WM did not improve the total remission rate, and Dengzhanhua or Xueshuantong injection plus WM did not lower the 24‐hour urinary protein excretion. Either Danhong (DH) or Dengzhanhua (DZH) injection plus WM was the preferable treatment for PNS based on SUCRA and cluster analyses of clinical remission and adverse events. However, considering that literature in this area is limited, these results need further validation. CHIs administered as adjuvants to WM showed favourable outcomes for PNS. DH + WM and DZH + WM might be the potential optimal therapies for PNS.

2015-09-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Yinxingye Capsule Intervened Vascular Endothelial Cell Apoptosis of Hyperhomocysteinemia Rats: an Experimental Study].

Article

作者: Xu, Zhi-bing ; Li, Jun ; Zhu, Jie ; Wang, Wei-dong ; Gu, Ren-yue ; Ma, Jin-miao ; Zhang, Li-fen ; Xi, Xi-xiang ; Jia, Jing-ying ; Zhang, Li-wei ; Wang, Yi

OBJECTIVE:

To explore targets of Chinese herbal medicine at cellular and molecular leve1s through an experimental study on Yinxingye Capsule (YC) intervening vascular endothelial cell apoptoeis of hyperhornocysteinemia (HHcy) rats.

METHODS:

The HHcy model was prepared in male Wistar rats. Totally 42 rats were randomly divided into 4 groups, i.e., the control group (n =10), the model group (n = 11), the YC group (n =11), the folic acid group (n =10). Carboxy methyl cellulose (CMC) solution (1%) was administered to rats in the control group by gastrogavage.3% methionine suspension at 1. 5 g/kg was administered to rats in the model group by gastrogavage. 3% methionine suspension at 1. 5 g/kg and folic acid suspension at 0. 06 g/kg was administered to rats in the folic acid group by gastrogavage. 3% methionine suspension at 1. 5 g/kg and YC at 0. 02 g/kg was administered to rats in the YC group by gastrogavage. Morphological changes of aortic tissue were observed by hematoxylin eosin (HE) staining. The plasma homocysteine (Hcy) level was detected in each group. The endothelium-dependent diastolic functions of the thoracic aorta on different concentrations of sodium nitroprusside (SNP) and acetylcholine (Ach) were detected. Gene expressions of Bcl-2-associated X protein (BAX), inducible nitric oxide synthase (iNOS), c-Fos, cellular inhibitor of apoptosis protein 2 (c-IAP2) were detected by real time polymerase chain reaction (RT-PCR).

RESULTS:

Pathological results showed that thickening aortic endothelium, swollen and desquamated endothelial cells. Few foam cells could be seen in the model group. Myoma-like proliferation of smooth muscle cells in tunica media could also be seen. These pathological changes were milder in the YC group and the folic acid group. Compared with the control group, plasma Hcy levels increased in the model group (P <0. 05). The endothelium-dependent diastolic rates at 10(-6) and 10(-4)mol/L Ach and 10(-7) -10(-3)mol/L SNP all decreased in the model group (P <0. 01, P <0. 05). Gene expressions of Bax, c-Fos, and iNOS increased, but c-IAP2 gene expressions decreased in the model group (all P <0. 05). Compared with the model group, plasma Hcy levels decreased in the YC group and the folic acid group (P <0. 05). The endothelium-dependent diastolic rates increased in the YC group and the folic acid group at various SNP concentrations except 10(-6) mol/L SNP in the folic acid group. The endothelium-dependent diastolic rates increased in the YC group and the folic acid group at 10(-6) and 10(-4)mol/L Ach (all P <0. 05). Gene expressions of Bax, c-Fos, and iNOS decreased in the YC group and the folic acid group, but c-IAP2 gene expression increased in the folic acid group (all P <0. 05).

CONCLUSION:

YC could reduce plasma Hcy levels, down-regulate gene expressions of Bax, c-Fos, and iNOS, thereby reducing apoptosis of vascular endothelial cells, improving vascular endothelial function, and delaying atherosclerotic process.

2013-01-01·Evidence-based complementary and alternative medicine : eCAM4区 · 医学

Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines

4区 · 医学

ArticleOA

作者: Yuwen, Ya ; Lu, Aiping ; Shi, Nan Nan ; Chan, Kam Wa ; Wang, Li Ying ; Han, Xue Jie

Objectives. This study was aimed to determine the therapeutic principle and identify Chinese Patent Medicine (CPM) with corresponding indications for hypertension treatment.Methods. Three rounds of Delphi survey were mailed among 40 cardiovascular integrative medicine specialists. Items with agreement of more than 80% respondents were included in the consensus.Results. According to majority of the panelists, CPM is suitable for most hypertensive patients and should be used according to traditional Chinese medicine pattern classification. CPM could be used alone for grade 1 hypertension and could be used in combination with Western biomedicine (WM) for both grade 2 and grade 3 hypertension. It is recommended that less than two CPMs are used simultaneously. For the treatment of grade 2 and 3 hypertension, CPM and WM should be taken separately. Recommended CPMs included Tianma Gouteng granule, Qiju Dihuang capsule, Jinkui Shenqi pill, Yinxingye tablet, Niuhuang Jiangya pill and Banxia Tianma pill. The indications of 4 CPMs were specified with symptoms related to TCM pattern classification by the experts.Conclusions. An expert consensus on CMP application was formed for the treatment of hypertension in the form of integrative medicine. A flow of IM hypertension management was proposed based on the results of the survey.

153

项与银杏叶提取物相关的新闻（医药）

2024-12-25

·财经大健康

医保局点名彻查，三款药涉多家上市公司

减肥药、整顿、彻查、医药拜访费、生物法案，为关键词图/视觉中国 No.1 国家监察委员会：深入整顿医药领域乱象 2024年12月22日，国家监察委员会向十四届全国人大常委会第十三次会议作了《关于整治群众身边不正之风和腐败问题工作情况的报告》。报告指出,国家监委调度各级监察机关配合有关部门重拳出击，严查靠医吃医、套取医保资金等腐败问题，狠刹吃回扣、收红包等行业歪风。全国共立案5.2万人，处分4万人，移送检察机关2634人。其中，留置处级以上干部675人。推动规范医药领域采购、销售等制度机制，推进医疗机构检查检验结果互认共享，严厉打击“号贩子”。推动对全国510家医保定点医疗机构开展国家飞行检查，查实欺诈骗保机构124家，全国各级医保部门共追回医保资金242.3亿元。2024年较2022年同期，全国二级以上公立医疗机构出院次均费用下降5.7%，其中住院次均药品费用下降12.1%。医药领域腐败加重群众负担，损害医患关系，恶化行业风气，广为社会诟病。报告指出：深入整顿医药领域乱象，推动解决“看病难”“看病贵”等问题。 No.2 医保局点名彻查，三款药涉多家上市公司针对2024年公安部门侦破的大额医药领域虚开发票案，12月20日，国家医保局向全国医保部门发函，要求认真排查银杏叶提取物注射液、头孢唑肟钠注射液、水解蛋白口服溶液等涉案产品是否存在类似问题，尽快摸清挂网价格底数。医保局的发函明确提出：近日经济参考报《经参调查：一些药企经销商虚开发票形成非法利益链》报道指出，“一款名为‘银杏叶’的药品，底价每支8.5元，售价每支25.28元，医生每使用一支可提成四元；一款名为‘头孢唑肟钠’的药品，底价每支6.5元，售价每支16.5元，医生每使用一支可提成2.5元。经测算，药品提成金额普遍占药品开票价与底价差额的两成以上。” 上述遭到医保局明确点名的三款药物品种，涉及多家上市公司，直接引发相关公司股价的波动。其中，12月23日，科创板上市药企悦康药业的收盘价下跌超过14%。银杏叶提取物注射液悦康药业的核心产品。根据悦康药业2023年报，银杏叶提取物注射液销售量约为1.61亿支。其2020年上市招股书，2017年，银杏叶提取物注射液总销售收入为4.1亿元，公立医院销量占比达到74.90%。此外，产品也涉及“银杏叶”的康缘药业和益佰制药股价也分别下跌2.09%和4.61%，这两家公司的相关产品分别为银杏二萜内酯葡胺注射液、银杏达莫注射液。另一款被点名的药品头孢唑肟钠注射液，同样涉及多家上市公司。注射用头孢唑肟钠属于第三代头孢菌素，2023年全国院内市场的销售额超35亿元，同比增长达9.98%，市场规模在头孢类产品中位居第二。生产商有灵康药业、罗欣药业、振东制药等。 No.3 药明康德出售业务，应对生物法案药明康德作出重大股权调整，出售业务给美国股权投资基金，以应对美国生物法案。 12月24日，药明康德宣布，公司间接全资子公司WuXi ATU (Ireland)Holding Limited和WuXi ATU (Hong Kong) Limited与Altaris LLC（下称“Altaris”）签署了股权购买协议。 Altaris是一家设立于美国的专注于医疗保健行业的股权投资基金。根据协议，药明康德将把其持有的Advanced Therapies（WuXi ATU业务的美国运营主体），及Oxford Genetics（WuXi ATU业务的英国运营主体）的全部股权，以现金对价方式转让给Altaris。本次交易涉及的Advanced Therapies和Oxford Genetics在2024年1至11月的合计营业收入约折合人民币9.8亿元，占药明康德最近一个会计年度经审计营业收入的2.4%。药明康德预计，本次交易将不会对公司业绩和经营状况产生重大影响。公司将继续贯彻“跟随客户”和“跟随分子”的战略目标，不断践行“让天下没有难做的药，难治的病”的愿景。本次交易需按照股权购买协议的约定完成交割，预计将在2025年上半年完成。 WuXi ATU业务，主要涉及细胞治疗、基因治疗及其他高端治疗的开发、制造和商业化。美国生物安全法案的提出，对药明康德的WuXi ATU业务拓展造成了实质影响。中报业绩显示，WuXi ATU业务实现收入同比下降19.43%。这表明，法案的不确定性已经对药明康德的业务发展和全球市场布局产生了负面影响。此次剥离，或是面对美国生物安全法案的挑战，药明康德采取的应对措施。 No.4 长风药业递表港交所，不提“医药拜访费”了近期，A转H的企业愈来愈多。日前，长风药业向港交所提交上市申请书，联席保荐人为中信证券（香港）有限公司和招银国际融资有限公司。招股书显示，长风药业专注于呼吸系统疾病领域药物的研发、生产和销售。目前，公司已有五款商业化产品，包括吸入液体制剂CF017、CF036、CF038、GW006以及鼻喷雾剂CF018。此番赴港上市之前，长风药业曾于2021年、2023年两次申请于科创板上市，但均无果而终。在闯关科创板的招股书“市场推广费”一栏中，长风药业列出了“医院拜访费”，2021年和2022年，该费用分别为311.67万元和2385.76万元。而在港交所的招股书中，长风药业采用的则是粗略的方式公布。从而，“医院拜访费”消失了。一直以来，医药行业市场推广费被认为是商业贿赂的高发区。为何长风药业赴港招股书却避开披露市场推广费事宜？长风药业称，“公司的上市申请书和相关材料是在遵守香港联交所合规要求的前提下编制披露的，且符合香港联交所的财务披露要求，不存在刻意隐藏披露或避开披露的情形。” No.5 诺和诺德跌倒，礼来上位？近日，减肥药巨头诺和诺德股价大跌约18%，市值蒸发625亿美元（约合4600亿元人民币）。其市值急剧下跌的主要原因是该公司公布的减肥药物CagriSema临床数据未能达到市场预期， CagriSema是诺和诺德开发的一种用于治疗肥胖症或超重成人的药物，它是一种固定剂量的复方制剂。这种药物设计为每周一次的皮下注射，通过减少饥饿感、增加饱腹感来帮助患者减少食量和降低卡路里摄入，从而实现体重减轻。诺和诺德最新公布的临床3期试验REDEFINE 1的主要结果中CagriSema平均帮助患者减重22.7%，低于公司预期的25%。此外，仅57%的患者能够接受最高剂量，表明该药可能存在较难忍受的副作用。这一低于预期数据，对诺和诺德来说打击不小。此前，诺和诺德凭借Wegovy打开了肥胖症的市场，本想以差异化产品组合，打出王牌CagriSema以夺取先机，以期超越礼来的减肥药Zepbound，迭代减肥药市场霸主地位，然而事与愿违，诺和诺德的挫折无疑让竞争对手礼来公司受益。 12月20日，诺和诺德盘前一度暴跌近30%，市值蒸发千亿美元，其减肥药竞争对手礼来则盘前大涨超12%。目前，礼来已经占据了美国减肥药市场约40%的份额。诺和诺德和礼来在减肥市场的份额将平分秋色。有分析师预计，当供应问题得到解决后，这种势均力敌的态势可能被打破，礼来或有望在减肥药市场取代诺和诺德成为领导者，过去几年，诺和诺德和礼来在减肥药领域的双寡头格局为投资者创造了超过1万亿美元的市值增长。转载爆料进读者群扫码添加小编往期 · 推荐别错过优质内容，记得设置星标或在看哟

带量采购

2024-12-25

·echemi

Investigation of Three Drugs for Invoice Fraud Affects Stock Market Fluctuations

On December 20, China’s National Healthcare Security Administration (NHSA) issued an official letter to provincial and regional healthcare bureaus, requiring an investigation into ginkgo leaf extract injection, cefotaxime sodium injection, and hydrolyzed protein oral solution to determine whether these products are involved in invoice fraud schemes similar to recent cases in the pharmaceutical industry. The investigation aims to clarify the actual net prices of these products. The NHSA's letter highlighted that, according to a report by Economic Information Daily, public security authorities cracked two pharmaceutical invoice fraud cases in 2022 and 2024. These investigations revealed a dual-pricing system for pharmaceuticals, including a "list price" and a "net price." Manufacturers sold medicines to distributors at the list price, and distributors then sold them to medical institutions. After transactions, the price difference between the list price and net price was refunded to the distributors. This price gap, disguised through fraudulent invoices, was then withdrawn as profits or used for commercial bribery, artificially inflating drug prices from the source. For instance, the report detailed that the net price of ginkgo leaf extract injection was CNY 8.5 per unit, while its list price reached CNY 25.28 per unit, generating a commission of CNY 4 per unit for doctors. Similarly, cefotaxime sodium injection's net price was CNY 6.5 per unit, and its list price was CNY 16.5 per unit, with a doctor commission of CNY 2.5 per unit. Commissions commonly accounted for over 20% of the price gap between the list and net prices. The mentioned drugs are linked to several listed companies, leading to significant stock price fluctuations upon the market opening on Monday. Among these, Sci-Tech Innovation Board-listed Yekang Pharmaceutical saw its stock price plunge over 18% intraday, closing down more than 14% due to its flagship ginkgo leaf extract injection being named. According to Yekang’s IPO prospectus, this product's hospital sales volume and revenue grew significantly from 2017 to 2019. Companies such as Kangyuan Pharmaceutical and Yibai Pharmaceutical, also involved in ginkgo products, saw their stock prices decline by 2.09% and 4.61%, respectively. Cefotaxime sodium injection also triggered major declines in the shares of multiple companies. As the second-largest product in cefalosporins with a national hospital market sales value exceeding CNY 3.5 billion in 2023, the drug’s inclusion in the investigation sent Lingkang Pharmaceutical's stock price to a daily limit down, while Luoxin Pharmaceutical fell 6.12% and Zhendong Pharmaceutical dropped 5.41%. Notably, cefotaxime sodium injection remains outside China’s national centralized procurement program despite widespread use of other cefalosporins within the program.

IPO生物类似药

2024-12-23

·医药投资部落

医保局点名彻查，多家上市药企股价暴雷

12月20日，国家医保局针对公安部门侦破的医药领域虚开发票案，向各省、自治区、直辖市及新疆生产建设兵团医保局发函，要求认真排查银杏叶提取物注射液、头孢唑肟钠注射液、水解蛋白口服溶液等涉案产品是否存在类似问题，尽快摸清挂网价格底数。医保局的发函明确提出：近日经济参考报《经参调查：一些药企经销商虚开发票形成非法利益链》报道，2022年、2024年，公安部门先后侦破两起医药领域虚开发票案。调查发现，“一些药品存在两套价格，即‘底价’和‘开票价’”，“药企先把药品按‘开票价’销售给经销商，再由经销商销售给医疗机构，交易完成后药企再把‘开票价’与‘底价’之间的差价返还给经销商”，“巨大的价格差通过虚开发票手段‘洗白’并‘提现’，成为不法经销商牟利和商业贿赂的资金来源，导致部分药品价格从源头就虚高”。报道指出，“一款名为‘银杏叶’的药品，底价每支8.5元，售价每支25.28元，医生每使用1支可提成4元；一款名为‘头孢唑肟钠’的药品，底价每支6.5元，售价每支16.5元，医生每使用1支可提成2.5元。经测算，药品提成金额普遍占药品开票价与底价差额的两成以上。上述遭到医保局明确点名的三款药物品种，涉及多家上市公司，直接引发周一开盘后相关公司股价的剧烈波动。其中，科创板上市药企悦康药业的股价反应最为强烈：盘中跌幅一度超过18%，收盘价下跌超过14%。主要原因在于，悦康药业的核心产品银杏叶提取物注射液是首当其冲被点名的品种。根据悦康药业2020年上市时发布的招股书，2017年，公司银杏叶提取物注射液总销售收入为4.1亿元，公立医院销量占比达到74.90%。 2018年、2019年，这款产品总销售收入均突破十亿元大关，分别达到10.4亿元、11.28亿元，公立医院销量占比分别达到80.44%、83.36%。悦康药业的股价之所以出现如此之大的波动，显然是投资者将医保局发函中的“银杏叶”产品与公司的银杏叶提取物注射液关联了起来。此外，产品也涉及“银杏叶”的康缘药业和益佰制药股价也分别下跌2.09%和4.61%，这两家公司的相关产品分别为银杏二萜内酯葡胺注射液、银杏达莫注射液。另一款被点名的药品头孢唑肟钠注射液，同样引发多家上市公司股价大跌。注射用头孢唑肟钠属于第三代头孢菌素，2023年全国院内市场的销售额超35亿元，同比增长达9.98%，市场规模在头孢类产品中位居第二。 2024年12月23日，生产头孢唑肟钠注射液产品的灵康药业股价跌停（-10%），罗欣药业下跌6.12%，振东制药下跌5.41%。值得指出的是，目前临床普遍使用的头孢菌素产品，基本已经纳入了国家集采，只剩一个头孢唑肟钠注射液尚未进入集采。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

IPO

100 项与银杏叶提取物相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
动脉硬化闭塞症	中国	Dr. Willmar Schwabe GmbH & Co. KG	2001-04-17
血管性痴呆	中国	Dr. Willmar Schwabe GmbH & Co. KG	2001-04-17
间歇性跛行	中国	Dr. Willmar Schwabe GmbH & Co. KG	2001-04-17
脑卒中	中国	Dr. Willmar Schwabe GmbH & Co. KG	2001-04-17